Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an announcement.
Pharmaron Beijing Co., Ltd. reported its annual financial results for the year ending December 31, 2024, showing a 6.4% increase in revenue to RMB12,275.8 million and a 12% rise in profit attributable to owners of the parent to RMB1,793.4 million compared to the previous year. Despite a decrease in net cash flows from operating activities by 6.4%, the company proposed a final dividend of RMB2.0 per 10 shares, reflecting its continued commitment to shareholder returns.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in China, operating within the pharmaceutical industry. The company focuses on providing drug research and development services, which include laboratory and manufacturing services to pharmaceutical and biotech companies.
YTD Price Performance: 10.53%
Average Trading Volume: 839
Technical Sentiment Signal: Sell
Current Market Cap: €5.75B
Find detailed analytics on 3759 stock on TipRanks’ Stock Analysis page.